

Please replace the paragraph beginning at page 23, line 10, with the following rewritten paragraph:

2
A --We turn now to the embodiment directed to a method of treating a patient in need of increased nitric oxide bioactivity, said method comprising administering to said patient a therapeutically effective amount of inhibitor of glutathione-dependent formaldehyde dehydrogenase. This embodiment may be referred to as the third embodiment herein.--

IN THE CLAIMS:

Please amend Claim 15 to be as follows:

3
A 15. (Amended.) A method for treating a patient in need of increased nitric oxide bioactivity, said method comprising administering to said patient a therapeutically effective amount of inhibitor of glutathione-dependent formaldehyde dehydrogenase.

Remarks

The specification has been amended at pages 3 and 23 and Claim 15 has been amended to recite that the treating agent is inhibitor of glutathione-dependent formaldehyde dehydrogenase rather than glutathione-dependent formaldehyde dehydrogenase.

That inhibitor of glutathione-dependent formaldehydes dehydrogenase is contemplated for the third embodiment is indicated in the application as filed at page 3, lines 3-5.

That inhibitor is meant as the treating agent for the third embodiment is indicated in the application as filed at page 24, lines 5-8 and page 24, lines 15-18 and at least by working Examples IV, V, X, XII and XIV.


Furthermore, Claim 20 as filed indicates that the treating agent for Claim 15 is inhibitor of glutathione-dependent formaldehyde dehydrogenase.

Attached hereto is a marked-up version of the changes made to the specification and claims by the current amendment. The attached page is captioned VERSION WITH MARKINGS TO SHOW CHANGES MADE.

Please enter this amendment.

Respectfully submitted,

JONES, TULLAR & COOPER, P.C.

By: 
Eric S. Spector
Reg. No. 22,495

JONES, TULLAR & COOPER, P.C.
P.O. Box 2266 Eads Station
Arlington, Virginia 22202
703-415-1500

Case Duke File No. 1838

Date: March 22, 2001



VERSION WITH MARKINGS TO SHOW CHANGES MADE

IN THE SPECIFICATION:

The paragraph beginning at line 15 of page 3 has been amended as follows:

Still another embodiment herein is directed to increasing NO bioactivity for pharmacological effect or in the case of diseases associated with a deficiency of NO. This embodiment is directed to a method of treating a patient in need of increased nitric oxide bioactivity, said method comprising administering to said patient a therapeutically effective amount of inhibitor of glutathione-dependent formaldehyde dehydrogenase.

The paragraph beginning at line 10 at page 23 has been amended as follows:

We turn now to the embodiment directed to a method of treating a patient in need of increased nitric oxide bioactivity, said method comprising administering to said patient a therapeutically effective amount of inhibitor of glutathione-dependent formaldehyde dehydrogenase. This embodiment may be referred to as the third embodiment herein.

IN THE CLAIMS:

Claim 15 has been amended as follows:

15. A method for treating a patient in need of increased nitric oxide bioactivity, said method comprising administering to said patient a therapeutically effective amount of inhibitor of glutathione-dependent formaldehyde dehydrogenase.